<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04551534</url>
  </required_header>
  <id_info>
    <org_study_id>DNLI-B-0001</org_study_id>
    <nct_id>NCT04551534</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Healthy Volunteers</brief_title>
  <official_title>A First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of DNL201 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Denali Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Denali Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, randomized, double-blind, placebo-controlled, single- and&#xD;
      multiple-ascending oral dose study conducted in three parts.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Actual">August 8, 2018</completion_date>
  <primary_completion_date type="Actual">August 8, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs) including serious adverse events (SAEs), and discontinuations due to TEAEs</measure>
    <time_frame>Up to 20 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter: Maximum observed concentration (Cmax) of DNL201 in plasma</measure>
    <time_frame>Up to 10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter: Time to maximum observed concentration (Tmax) of DNL201 in plasma</measure>
    <time_frame>Up to 10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter: The area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞) of DNL201 in plasma (single dosing only)</measure>
    <time_frame>Up to 10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter: Area under the concentration-time curve from time zero to the time of last quantifiable concentration (AUC[0-last]) of DNL201 in plasma</measure>
    <time_frame>Up to 10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter: The area under the concentration-time curve over a dosing interval (AUC0-τ) of DNL201 in plasma (multiple dosing only)</measure>
    <time_frame>Up to 10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter: Apparent terminal elimination half-life (t1/2) of DNL201 in plasma</measure>
    <time_frame>Up to 10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of DNL201 in cerebrospinal fluid (CSF) (following selected single and multiple doses)</measure>
    <time_frame>Up to 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pharmacodynamics of DNL201 in whole blood as measured by the percent change from baseline in pS935</measure>
    <time_frame>Up to 10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>DNL201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: Single-ascending dose cohorts; Part 2: Multiple-ascending dose cohorts (10 days); Part 3: Additional multiple-dose cohort (10 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part 1: Single-ascending dose cohorts; Part 2: Multiple-ascending dose cohorts (10 days); Part 3: Additional multiple-dose cohort (10 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DNL201</intervention_name>
    <description>Oral dose(s)</description>
    <arm_group_label>DNL201</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral dose(s)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index 18.5 to 35.0 kg/m², inclusive, and body weight of at least 50.0 kg at&#xD;
             screening&#xD;
&#xD;
          -  In good health, determined by no clinically significant findings from medical history,&#xD;
             physical examination, and vital sign measurements&#xD;
&#xD;
          -  Women of non-childbearing potential and men using contraceptive measures&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History of clinically significant hematological, renal, pancreatic, gastrointestinal,&#xD;
             hepatic, cardiovascular, metabolic, endocrine, immunological, allergic disease, or&#xD;
             other major disorders&#xD;
&#xD;
          -  History of asthma, chronic obstructive pulmonary disease, or emphysema&#xD;
&#xD;
          -  Clinically significant neurologic disorder&#xD;
&#xD;
          -  History of stomach or intestinal surgery or resection&#xD;
&#xD;
          -  History of malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danna Jennings, MD</last_name>
    <role>Study Director</role>
    <affiliation>Denali Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Site(s)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>05247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>September 10, 2020</last_update_submitted>
  <last_update_submitted_qc>September 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

